A racemic mixture of D- and L-AFMT. L-AFMT is reported to selectively inhibt against gut bacteria E. faecalis pyridoxal-5′-phosphate (PLP)-dependent tyrosine decarboxylase (TyrDC)-, but not aromatic amino acid decarboxylase (AADC)-, mediated L-dopa decarboxylation (IC50 = 4.7 μM/cell-free, 1.4 μM/in E. faecalis cultures; 20% human AADC inhibition at 650 μM) via covalent adduct formation with TyrDC co-factor PLP. When co-administered with L-dopa (10 mg/kg) and the AADC inhibitor carbidopa (30 mg/kg) to gnotobiotic mice colonized with E. faecalis, L-AFMT (25 mg/kg) significantly increases L-dopa peak serum concentration.
Covalent inhibtor against L-dopa decarboxylation by gut bacteria E. faecalis tyrosine decarboxylase (TyrDC), but not aromatic amino acid decarboxylase (AADC).
The human gut microbiota metabolizes the Parkinson's disease medication Levodopa (l-dopa), potentially reducing drug availability and causing side effects. However, the organisms, genes, and enzymes responsible for this activity in patients and their susceptibility to inhibition by host-targeted drugs are
Preguntas
Revisiones
★★★★★ Sin puntuación
Filtros activos
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
